© July 2024| IJIRT | Volume 11 Issue 2 | ISSN: 2349-6002

A Review on Pulmonary Devices, Respiratory Disorders, and Their Management

P.Sreevidya[1], D.Sailaja[2], B.Manasa[2], O.Ravindra babu[2], M.Surya Prakash[2]
[1]Department of pharmaceutics, Hindu college of pharmacy
[2] Hindu college of pharmacy

Abstract: Pulmonary drug delivery systems represent a pivotal advancement in the treatment of respiratory diseases, offering direct medication administration to the lungs for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These systems provide several advantages, including rapid onset of action, local targeting with high drug concentrations, and reduced systemic side effects. The primary types of pulmonary delivery devices include metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, each with unique mechanisms and specific use cases. Emerging technologies, such as smart inhalers and nanoparticle-based systems, are enhancing delivery efficacy and patient adherence. Key considerations for effective pulmonary drug delivery involve optimizing particle size for deep lung deposition, ensuring formulation stability, and designing user-friendly devices. With ongoing research and technological advancements, pulmonary drug delivery continues to improve therapeutic outcomes and patient quality of life in respiratory disease management.

Key words: Nanotechnology, pulmonary diseases, pulmonary devices, pulmonary drug delivery.

INTRODUCTION

A significant development in the management of respiratory disorders, pulmonary drug delivery devices allow for the direct delivery of medication to the lungs for ailments like cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma. Rapid beginning of action, local targeting at high drug concentrations, and fewer systemic side effects are merely a few benefits of these systems. Metered dosage inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers are the three main categories of pulmonary delivery devices; each has a distinct mechanism and set of applications. New technologies are improving patient adherence and delivery efficacy. Examples include nanoparticle-based systems and smart inhalers. Optimising particle size for deep lung deposition, guaranteeing formulation stability, and creating user-friendly devices are crucial factors for efficient pulmonary medication administration. Pulmonary drug administration continues to enhance treatment results and patient quality of life in the management of respiratory diseases because to continuous research and technological developments.

Advantages: Pulmonary drug delivery systems offer several advantages:

1. Rapid Onset of Action: Medication is delivered directly to the lungs, allowing for quick absorption and fast therapeutic effects, which is crucial in treating acute conditions like asthma attacks.
2. Targeted Delivery: Drugs are delivered directly to the site of action in the respiratory system, enhancing effectiveness and minimizing systemic side effects.
3. Lower Doses Required: Direct delivery to the lungs means lower doses can be used to achieve the desired therapeutic effect, reducing the risk of side effects.

Disadvantages: Pulmonary drug delivery systems have several disadvantages:

1. Device Dependency: Effective delivery often depends on the correct use of inhalers or nebulizers, which can be challenging for some patients, especially children and the elderly.
2. Variable Drug Deposition: Factors such as breathing patterns, lung condition, and the patient's ability to use the device correctly can affect how much of the drug reaches the target area.

Applications: Pulmonary drug delivery systems are used in a variety of medical applications, primarily targeting respiratory and systemic conditions. Key applications include:

1. Asthma: Inhalers and nebulizers deliver bronchodilators and corticosteroids directly to the lungs to relieve and prevent asthma symptoms.
2. Chronic Obstructive Pulmonary Disease (COPD): Medications such as bronchodilators, corticosteroids, and combination inhalers help manage symptoms and improve lung function.
3. Cystic Fibrosis: Nebulized antibiotics and mucolytics help manage respiratory infections and reduce mucus viscosity, improving lung function and quality of life.

Dosage forms of Pulmonary drug delivery systems: Pulmonary drug delivery systems utilize various dosage forms to deliver medication directly to the lungs. These include:

1. Metered-Dose Inhalers (MDIs):
   - Pressurized MDIs: Utilize a propellant to deliver a specific dose of medication in aerosol form.
   - Breath-Actuated MDIs: Release the drug automatically when the patient inhales.
2. Dry Powder Inhalers (DPIs):
   - Single-Dose DPIs: Require the patient to load a capsule or blister containing the drug powder before each use.
   - Multi-Dose DPIs: Contain multiple doses of the drug in a single device, typically in a reservoir or blister strip.
3. Nebulizers:
   - Jet Nebulizers: Use compressed air to convert liquid medication into a mist.
   - Ultrasonic Nebulizers: Utilize ultrasonic waves to produce a fine mist from liquid medication.
4. Soft Mist Inhalers (SMIs):
   - Create a slow-moving, fine mist of medication, improving deposition in the lungs with less effort from the patient.

Nano therapeutics for pulmonary drug delivery: Nanotherapeutics for pulmonary drug delivery represent a promising field that leverages nanotechnology to overcome biological barriers and enhance therapeutic efficacy. Here are key aspects and strategies involved:

1. Nanoparticle Design and Formulation:
   - Size and Surface Properties: Nanoparticles are designed to optimize size (typically < 500 nm) for efficient deposition in the lungs and surface properties (e.g., charge, hydrophobicity) to facilitate interaction with lung epithelial cells.
2. Targeting Strategies:
   - Active Targeting: Incorporating targeting ligands (e.g., antibodies, peptides) on nanoparticle surfaces to enhance specificity for receptors on diseased cells (e.g., cancer cells, inflamed tissues).
   - Passive Targeting (EPR Effect): Exploiting the Enhanced Permeability and Retention (EPR) effect in diseased lung tissues to accumulate nanoparticles selectively.
3. Drug Encapsulation and Delivery:
   - Encapsulation Efficiency: Efficient loading of drugs into nanoparticles to protect them from degradation and facilitate controlled release.
4. Biological Barriers Overcome:
   - Mucus and Clearance Mechanisms: Nanoparticles can bypass mucociliary clearance by optimizing size and surface properties to adhere to and penetrate mucus layers.

Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery: Physicochemical properties play a crucial role in determining the fate of nanoparticles in pulmonary drug delivery. Here are some key properties and their impact:

1. Deposition Efficiency: Nanoparticles with diameters typically less than 500 nm are ideal for efficient deposition in the lungs. Smaller particles can penetrate deeper into the lung tissue and reach target cell.
2. Interaction with Mucus: Surface charge influences nanoparticle interaction with mucus layers. Positively charged particles may adhere more readily to negatively charged mucins, potentially increasing residence time. However, they may also induce mucociliary clearance.
3. Surface Coating and Functionalization: Polyethylene glycol (PEG) coating reduces opsonization and clearance by the immune system, thereby extending circulation time and enhancing pulmonary retention.

Advances in Pulmonary Drug Delivery: Advances in pulmonary drug delivery have significantly enhanced the efficacy, safety, and patient compliance of treatments for respiratory diseases. Here are several notable advancements:

1. Nanotechnology and Nanoparticles:
   - Targeted Delivery: Nanoparticles can be engineered to target specific cells or tissues within the lungs, improving drug efficacy while minimizing systemic side effects.
2. Dry Powder Inhalers (DPIs) and Nebulizers:
   - Improved Formulations: DPIs and nebulizers have been refined to deliver drugs more efficiently to the lungs, enhancing bioavailability and reducing variability in drug delivery.
3. Biologics and Gene Therapy:
   - Inhaled Biologics: Therapeutic proteins, antibodies, and nucleic acids can now be delivered directly to the lungs via inhalation, offering targeted treatment for diseases like asthma, cystic fibrosis, and lung cancer.

Mechanisms of Pulmonary Drug Administration:

1. Deposition in the Respiratory Tract:
   - Inhalation devices deliver drug aerosols or dry powder formulations to the respiratory tract.
2. Absorption into Bloodstream:
   - Drugs can be absorbed directly into the pulmonary capillary circulation from the alveolar epithelium.
3. Local Action:
   - Drugs can exert local effects within the lungs, such as bronchodilation, anti-inflammatory effects, or treating infections.

Nano-in-Microparticles for Pulmonary Drug Delivery: Nano-in-microparticles (NiMPs) represent an innovative approach in pulmonary drug delivery, combining the advantages of both nanoparticles (NPs) and microparticles (MPs). Here's how NiMPs work and their potential advantages:

Mechanism of Nano-in-Microparticles (NiMPs):

1. Structure and Composition:
   - NiMPs consist of nanoscale drug-loaded particles (nanoparticles) encapsulated within a larger matrix (microparticles).
   - The nanoparticles can vary in size (typically < 200 nm) and are dispersed or embedded within the microparticle matrix (typically 1-5 μm).

Applications of Nano-in-Microparticles in Pulmonary Drug Delivery:

- Respiratory Diseases: NiMPs are particularly promising for treating chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They offer enhanced therapeutic efficacy and reduced dosing frequency compared to traditional formulations.
- Biologics and Gene Therapy: NiMPs can encapsulate biologics (e.g., proteins, antibodies) or genetic material (e.g., siRNA, plasmid DNA) for targeted delivery to lung cells, offering potential treatments for genetic disorders or lung cancer.

Types of pulmonary diseases: Pulmonary diseases, also known as respiratory diseases, encompass a wide range of conditions that affect the lungs and other parts of the respiratory system. Here are the major types of pulmonary diseases:

1. Obstructive Lung Diseases: These diseases are characterized by airflow obstruction, making it difficult for air to leave the lungs.

- Asthma: A chronic condition where the airways become inflamed and narrow, leading to wheezing, shortness of breath, and coughing. Triggers include allergens, exercise, and infections.
- Chronic Obstructive Pulmonary Disease (COPD): A progressive disease that includes chronic bronchitis and emphysema. It is primarily caused by smoking and leads to difficulty breathing, chronic cough, and frequent respiratory infections.

2. Restrictive Lung Diseases: These diseases are characterized by a reduction in lung volume, making it difficult for the lungs to expand fully.

- Pulmonary Fibrosis: A condition marked by the scarring of lung tissue, leading to stiffness and difficulty breathing.
- Sarcoidosis: An inflammatory disease that can affect multiple organs, including the lungs,

leading to granulomas (small areas of inflammation) in the lung tissue.

3. Infectious Lung Diseases: These are caused by infections that affect the respiratory system.
- Pneumonia: An infection that inflames the air sacs in one or both lungs, which can fill with fluid or pus. It can be caused by bacteria, viruses, or fungi.
- Tuberculosis (TB): A serious infectious disease caused by the bacteria Mycobacterium tuberculosis, primarily affecting the lungs but can spread to other organs.

4. Pulmonary Vascular Diseases: These diseases affect the blood vessels within the lungs.
- Pulmonary Hypertension: High blood pressure in the arteries of the lungs, which can lead to heart failure.
- Pulmonary Embolism: A blockage in one of the pulmonary arteries in the lungs, usually caused by blood clots that travel from the legs.

5. Lung Cancer: A group of cancers that start in the lungs. The main types are:
- Non-Small Cell Lung Cancer (NSCLC): The most common type, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
- Small Cell Lung Cancer (SCLC): A less common type that tends to spread more quickly than NSCLC.

6. Environmental and Occupational Lung Diseases: These are caused by exposure to harmful substances in the environment or workplace.
- Asbestosis: A chronic lung disease caused by inhaling asbestos fibers, leading to lung tissue scarring.
- Silicosis: A lung disease caused by inhaling silica dust, leading to inflammation and scarring.

Evaluation of pulmonary drug delivery system: Evaluating pulmonary drug delivery systems involves a comprehensive assessment of various parameters to determine their efficacy, safety, and suitability for clinical use. Key aspects of this evaluation include pharmacokinetics, pharmacodynamics, patient adherence, device performance, and clinical outcomes. Here is an outline of the critical factors and methods used in the evaluation:

1. Pharmacokinetics and Pharmacodynamics
- Absorption and Distribution: Measuring how quickly and effectively the drug is absorbed into the lung tissues and systemic circulation.
- Bioavailability: Assessing the fraction of the administered dose that reaches the target site in an active form.

2. Clinical Efficacy
- Symptom Relief: Measuring the improvement in respiratory symptoms, such as breathlessness, wheezing, and coughing.
- Lung Function Tests: Using spirometry and other pulmonary function tests to quantify improvements in lung capacity and airflow.

3. Safety and Tolerability
- Local Adverse Effects: Evaluating any local side effects such as throat irritation, cough, or bronchospasm.

4. Device Performance
- Particle Size Distribution: Ensuring the aerosol particles are within the optimal range (1-5 microns) for deep lung deposition.

5. Patient Adherence and Satisfaction
- Inhaler Technique: Evaluating how well patients can use the device correctly, which is critical for effective treatment.
- Convenience and Portability: Assessing the device's design and how it fits into patients' daily lives.

Methods for Evaluation:
- In Vitro Testing: Laboratory tests to analyze the physical and chemical properties of the drug formulation and aerosol performance.
- In Vivo Studies: Animal and human clinical trials to assess pharmacokinetics, pharmacodynamics, efficacy, and safety.

In vitro studies of pulmonary drug delivery: In vitro studies are critical in the development and evaluation of pulmonary drug delivery systems. Here are the key aspects of in vitro studies for pulmonary drug delivery:

Key Aspects of In Vitro Studies:
1. Aerosol Characterization
   - o Particle Size Distribution: The aerodynamic diameter of particles should ideally be between 1

and 5 microns for optimal deposition in the lower respiratory tract. Techniques such as cascade impaction, laser diffraction, and dynamic light scattering are used to measure particle size distribution.

2. Formulation Stability
   - Chemical Stability: The chemical integrity of the drug should be maintained throughout its shelf life. High-performance liquid chromatography (HPLC) and mass spectrometry are commonly used to assess this.
   - Physical Stability: Ensuring the physical state of the drug (e.g., crystallinity, amorphous form) remains stable during storage and usage. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) are typical methods for analysis.
3. Device Performance
   - Functionality Testing: Evaluating the mechanics of the device, including actuation force, dose consistency, and breath activation in the case of DPIs.
4. Deposition Studies
   - Cascade Impactor Studies: Using devices like the Andersen Cascade Impactor (ACI) or Next Generation Impactor (NGI) to simulate human respiratory tract conditions and assess where particles are likely to deposit.

Methods and Techniques:
1. Cascade Impaction: Separates aerosol particles based on their aerodynamic diameter to determine particle size distribution.
2. Laser Diffraction: Measures particle size distribution by analyzing the pattern of light scattered by aerosol particles.
3. High-Performance Liquid Chromatography (HPLC): Quantifies the chemical composition and stability of the drug.
4. Mass Spectrometry: Provides detailed molecular information about the drug compound.

Applications and Outcomes:
- Optimization of Formulations: Fine-tuning the physical and chemical properties of the drug to enhance performance.
- Device Design Improvements: Modifying inhaler designs based on performance data to improve usability and efficiency.

In vivo studies of pulmonary drug delivery: In vivo studies of pulmonary drug delivery systems are essential for understanding how these systems perform in living organisms, including humans. Here are the key aspects and methodologies involved in in vivo studies of pulmonary drug delivery:

Key Aspects of In Vivo Studies:
1. Pharmacokinetics (PK)
   - Absorption: Evaluating how the drug is absorbed through the lung tissue into the bloodstream.
   - Distribution: Studying how the drug distributes throughout the body and reaches the target site.
   - Metabolism: Understanding how the drug is metabolized, including the identification of metabolic pathways.
   - Excretion: Determining the routes and rates of drug elimination from the body.
2. Pharmacodynamics (PD)
   - Efficacy: Measuring the therapeutic effects of the drug, such as improvements in lung function, symptom relief, and reduction in disease exacerbations.
3. Safety and Tolerability
   - Local Adverse Effects: Monitoring for any adverse reactions in the lungs, such as irritation, inflammation, or bronchospasm.
   - Systemic Adverse Effects: Assessing potential side effects in other parts of the body, especially with high doses or prolonged use.
4. Clinical Efficacy
   - Lung Function Tests: Using spirometry and other pulmonary function tests to measure improvements in parameters like FEV1 (forced expiratory volume in one second) and peak expiratory flow rate (PEFR).

Methodologies for In Vivo Studies:
1. Animal Studies
   - Model Selection: Choosing appropriate animal models (e.g., rodents, dogs, primates) that mimic human respiratory physiology and disease conditions.
   - Administration: Delivering the drug via inhalation using specialized equipment like nose-only exposure chambers or whole-body exposure systems.
2. Human Clinical Trials

- Phase I Trials: Initial trials in healthy volunteers to assess safety, tolerability, and preliminary PK.
- Phase II Trials: Trials in patients to evaluate efficacy, optimal dosing, and further safety.
- Phase III Trials: Large-scale trials to confirm efficacy and safety in diverse patient populations and gather data for regulatory approval.
- Phase IV Trials: Post-marketing surveillance studies to monitor long-term safety and effectiveness in real-world settings.

Applications and Outcomes:

- Optimization of Dosing Regimens: Determining the most effective and safe dosing schedules.
- Safety Profiling: Identifying and mitigating potential adverse effects.

SUMMARY AND CONCLUSION

Many pulmonary drug delivery system formulations are available on the market right now, but sustained release medications via the pulmonary route are not. Research on the sustained release of drugs in various formulations for pulmonary drug delivery systems has even been conducted for many years.Research on the sustained release of drugs in various formulations for pulmonary drug delivery systems has even been conducted for many years. As sustained release research for pulmonary drug delivery offers benefits like local drug deposition in the lungs, drug dose reduction in formulation, frequency reduction, extended drug residence time in the lung, slowed drug absorption rate, decreased systemic exposure to the drug, and fewer incidences of side effects related to systemic exposure to the drug.Research on sustained release pulmonary drug delivery systems is therefore desperately needed, as it will provide several benefits over currently available formulations and address a number of issues related to the formulation of medication for pulmonary drug delivery systems.

Thus, since nanomedicine is safe, efficient, and has unique benefits, it is imperative to advance research in this area for the transport of drugs to the lungs.It is advised that sustained release aerosols be a focus of ongoing study because they present special potential and difficulties for the creation of pulmonary medication delivery systems. As a result, it is determined that more study on localised sustained release aerosols is crucial for the delivery of drugs to the lungs, particularly for treating potentially fatal respiratory conditions.

REFERENCES

[1] Courrier H.M., Butz N., Vandamme T.F., Pulmonary drug delivery systems: Recent developments and prospects. Critical Reviews In Therapeutic Drug Carrier Systems, 19 (4-5):425-498, (2002).

[2] Atkins P.J., Crowder T.M. The design and development of inhalation drug delivery systems. In: Hickey A. Pharmaceutical inhalation aerosol technology, 2nd ed. New York: Dekker; (2004).

[3] Rau J.L. The inhalation of drugs: advantages and problems. Respiratory Care 2005;50(3):367–382.

[4] Hohenegger M. Novel and Current Treatment concepts using

[5] pulmonary drug delivery. Curr Pharm Des 2010; 16(22): 2484-92.

[6] Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I:Physiological factors affecting therapeutic effectiveness ofaerosolized medications. Br J Clin Pharmacol 2003; 56(6): 588-99.

[7] McCalden T. Particulate systems for drug delivery to the lung. AdvDrug Del Rev 1990; 5: 253-63.

[8] Ray L, Polymeric nanoparticle-based drug/gene delivery for lung cancer, in nanotechnology-based targeted drug delivery systems for lung cancer, 2019; Chap. 4: 77–93

[9] Safari J and Zarnegar Z Advanced drug delivery systems: Nanotechnology of health design A review J Saudi Chem Soc 2014 18 85-99

[10] Jain, K.K. An overview of drug delivery systems. Drug Deliv. Syst. 2020, 2059, 1–54.

[11] S. Aryal, S.D. NathanAn update on emerging drugs for the treatment of idiopathic pulmonary fibrosisJ. Expert Opin. Emerg. Drugs, 23 (2) (2018), pp. 159-172

[12] S. Chennakesavulu, A. Mishra, A. Sudheer, et al.Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosisJ. Asian J. Pharm. Sci., 13 (1) (2018), pp. 91-100

[13] S.C. Schäfer, M. Funke-Chambour, S. BerezowskaIdiopathic pulmonary fibrosis-

epidemiology, causes, and clinical courseJ. Pathologe, 41 (1) (2020), pp. 46-51
[14] Chinnasamy Gandhimathi, Jayarama Reddy Venugopal, Subramanian Sundarrajan, Radhakrishnan Sridhar, Samuel Sam Wah Tay, Seeram Ramakrishna, Srinivasan Dinesh KumarBreathable medicine: pulmonary mode of drug deliveryJ. Nanosci. Nanotechnol., 15 (2015), pp. 2591-2604
[15] Ratemi E, SultanaShaik A, Al-Faraj A, et al. Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine. Clin Exp Allergy. 2016;46:1033–42.
[16] Wadhwa R, Aggarwal T, Thapliyal N, et al. Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma: Progress and Challenges Nanotechnology in Modern Animal
[17] Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251–62. Biotechnology. New York: Elsevier; 2019. p. 59–73.
[18] Khilnani GC and Banga A. Aerosol Therapy. The Indian Journal of ChestDiseases & Allied Sciences. 2008; 50 : 209-20.